Mads Hald Andersen

9.9k total citations · 1 hit paper
206 papers, 7.1k citations indexed

About

Mads Hald Andersen is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Mads Hald Andersen has authored 206 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Immunology, 98 papers in Oncology and 55 papers in Molecular Biology. Recurrent topics in Mads Hald Andersen's work include Immunotherapy and Immune Responses (124 papers), Immune Cell Function and Interaction (71 papers) and Cancer Immunotherapy and Biomarkers (57 papers). Mads Hald Andersen is often cited by papers focused on Immunotherapy and Immune Responses (124 papers), Immune Cell Function and Interaction (71 papers) and Cancer Immunotherapy and Biomarkers (57 papers). Mads Hald Andersen collaborates with scholars based in Denmark, Germany and United States. Mads Hald Andersen's co-authors include Per thor Straten, Inge Marie Svane, Jürgen C. Becker, David Schrama, Marco Donia, Lars Østergaard Pedersen, Morten Hansen, Eva Ellebæk, Shamaila Munir Ahmad and Trine Zeeberg Iversen and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Mads Hald Andersen

200 papers receiving 7.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effect of short-chain fatty acids on human monocyte-derived dendritic cells

2015 317 citations Claudia Nastasi, Charlotte M. Bonefeld et al. Scientific Reports profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mads Hald Andersen Denmark	43	4.7k	3.4k	2.6k	433	363	206	7.1k
Srinivas Nagaraj United States	23	9.2k 2.0×	4.7k 1.4×	2.5k 0.9×	298 0.7×	284 0.8×	34	11.6k
Allen T. Bruce United States	13	6.5k 1.4×	4.1k 1.2×	2.1k 0.8×	474 1.1×	200 0.6×	16	9.2k
Eduardo M. Sotomayor United States	51	6.6k 1.4×	4.9k 1.4×	3.9k 1.5×	419 1.0×	657 1.8×	198	11.1k
Paolo Serafini United States	29	5.9k 1.3×	2.9k 0.8×	1.5k 0.6×	179 0.4×	119 0.3×	39	7.3k
David O’Sullivan United States	16	5.2k 1.1×	2.4k 0.7×	3.3k 1.3×	554 1.3×	188 0.5×	26	8.7k
Francesco Novelli Italy	47	3.5k 0.7×	2.5k 0.7×	2.3k 0.9×	335 0.8×	304 0.8×	157	7.1k
Gerritje J. W. van der Windt Netherlands	26	6.4k 1.4×	2.7k 0.8×	3.7k 1.4×	753 1.7×	325 0.9×	43	10.4k
Jonathan D. Curtis United States	14	5.1k 1.1×	2.3k 0.7×	2.8k 1.1×	586 1.4×	171 0.5×	15	8.1k
Yuanyuan Zha United States	22	3.2k 0.7×	4.5k 1.3×	2.5k 1.0×	232 0.5×	104 0.3×	67	6.8k
Kenneth A. Frauwirth United States	22	4.3k 0.9×	2.1k 0.6×	1.8k 0.7×	450 1.0×	183 0.5×	29	6.6k

Countries citing papers authored by Mads Hald Andersen

Since Specialization

Citations

This map shows the geographic impact of Mads Hald Andersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mads Hald Andersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mads Hald Andersen more than expected).

Fields of papers citing papers by Mads Hald Andersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mads Hald Andersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mads Hald Andersen. The network helps show where Mads Hald Andersen may publish in the future.

Co-authorship network of co-authors of Mads Hald Andersen

This figure shows the co-authorship network connecting the top 25 collaborators of Mads Hald Andersen. A scholar is included among the top collaborators of Mads Hald Andersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mads Hald Andersen. Mads Hald Andersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Holmström, Morten Orebo, Morten Andersen, Sofie Traynor, et al.. (2023). Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow. Frontiers in Immunology. 14. 1240678–1240678. 5 indexed citations

Draghi, Arianna, Christopher A. Chamberlain, Mads Hald Andersen, et al.. (2023). Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma. Clinical Cancer Research. 29(19). 3937–3947. 11 indexed citations

Kopp, Katharina, Marion Chapellier, Evelina Martinenaite, et al.. (2022). CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment. OncoImmunology. 11(1). 2115655–2115655. 18 indexed citations

Andersen, Mads Hald. (2022). Tumor microenvironment antigens. Seminars in Immunopathology. 45(2). 253–264. 50 indexed citations

Andersen, Mads Hald. (2022). Immune modulatory vaccines: the safe way to inflame the tumor microenvironment & guide anti-cancer immunotherapies. Research at the University of Copenhagen (University of Copenhagen). 9(3). 401–407.

Ugel, Stefano, Marco Carretta, Stine Emilie Weis-Banke, et al.. (2021). Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade. Cancer Immunology Research. 9(11). 1316–1326. 41 indexed citations

Kjeldsen, Julie Westerlin, Cathrine Lund Lorentzen, Evelina Martinenaite, et al.. (2021). A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nature Medicine. 27(12). 2212–2223. 135 indexed citations

Draghi, Arianna, Cathrin Ritter, Tina Seremet, et al.. (2019). MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells. Cancer Immunology Research. 7(9). 1472–1484. 40 indexed citations

Pedersen, Ayako Wakatsuki, Katharina Kopp, Mads Hald Andersen, & Mai-Britt Zocca. (2018). Immunoregulatory antigens—novel targets for cancer immunotherapy. Chinese Clinical Oncology. 7(2). 19–19. 7 indexed citations

10.

Kallemose, Thomas, Göran Jönsson, Mats Jönsson, et al.. (2018). Immunoprofiles of colorectal cancer from Lynch syndrome. OncoImmunology. 8(1). e1515612–e1515612. 17 indexed citations

11.

Andersen, Mads Hald, et al.. (2017). P4537Prevalence of infective endocarditis in patients with gram positive cocci bacteraemia. European Heart Journal. 38(suppl_1).

12.

Nastasi, Claudia, Simon Fredholm, Andreas Willerslev-Olsen, et al.. (2017). Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells. Scientific Reports. 7(1). 14516–14516. 107 indexed citations

13.

Andersen, Rikke, Marco Donia, Eva Ellebæk, et al.. (2016). Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research. 22(15). 3734–3745. 234 indexed citations

14.

Donia, Marco, Rikke Andersen, Julie Westerlin Kjeldsen, et al.. (2015). Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. Cancer Research. 75(18). 3747–3759. 103 indexed citations

15.

Iversen, Trine Zeeberg, Lotte Engell-Noerregaard, Eva Ellebæk, et al.. (2013). Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase. Clinical Cancer Research. 20(1). 221–232. 100 indexed citations

16.

Ahmad, Shamaila Munir, Özcan Met, Marco Donia, et al.. (2013). HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients. Cancer Research. 73(6). 1764–1776. 58 indexed citations

17.

Sørensen, Rikke Bæk, Tania Køllgaard, Rikke Andersen, et al.. (2011). Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2. Cancer Research. 71(6). 2038–2044. 44 indexed citations

18.

Berntsen, Annika, Redas Trepiakas, Lynn Wenandy, et al.. (2008). Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy. 31(8). 771–780. 82 indexed citations

19.

Sørensen, Rikke Bæk, Inge Marie Svane, Per thor Straten, & Mads Hald Andersen. (2008). A survivin specific T-cell clone from a breast cancer patient displays universal tumor cell lysis. Cancer Biology & Therapy. 7(12). 1885–1887. 10 indexed citations

20.

Reker, Sine, Jürgen C. Becker, Inge Marie Svane, et al.. (2004). HLA‐B35‐restricted immune responses against survivin in cancer patients. International Journal of Cancer. 108(6). 937–941. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact